

A<sup>1</sup> biological activity, wherein said antisense nucleic acid is complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3).

Add the following new claims 9-15.

A<sup>2</sup> 9. (New) A method of treating a patient diagnosed as having a proliferative disease, said method comprising administering to said patient an antisense nucleic acid of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense nucleic acid is complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3).

10. (New) The method of claim 9, wherein said mammal is a human.

A<sup>2</sup> 11. (New) The method of claim 9, wherein said proliferative disease is cancer.

12. (New) The method of claim 11, wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.

13. (New) The method of claim 5, wherein said mammal is a human.

14. (New) The method of claim 5, wherein said proliferative disease is cancer.

15. (New) The method of claim 14, wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.